Jan 29, 2025 · Repeated brain injury quickens ALS onset and progression in mice. Repeated traumatic brain injuries (TBIs), which happen when the brain is damaged by external impacts such as a fall or a car accident, can accelerate the onset and progression of amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene, a new mouse study suggests.

Jan 8, 2025 · The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an estimated 32,800 cases in 2022 to about 36,300 in 2030, according to a new study from researchers with the Centers for Disease Control and Prevention (CDC).

Dec 30, 2024 · Read this story here. No. 8 – COYA 302 immune-modulating therapy shows promise in small early trial. Coya Therapeutics’ investigational therapy COYA 302 was found to slow ALS disease progression and lower levels of disease-related biomarkers in a small Phase 1 clinical trial. COYA 302 is a combination of an immune signaling molecule called interleukin-2 …

Jan 3, 2025 · That’s according to the study, “ Association between cardiometabolic diseases and the risk and progression of motor neuron diseases in Sweden: a population-based case-control study,” which was published in The Lancet Regional Health-Europe. “Our findings underscore the importance of considering [cooccurring health issues] in the treatment and management of …

Mar 4, 2024 · The new data comes from the PARADIGM Phase 2b study (NCT05357950), a fully enrolled clinical trial that’s testing oral PrimeC against a placebo in 68 adults with ALS. Participants had experienced their first symptoms within the prior 30 months and could continue to receive their standard ALS medications.. These findings come shortly after positive top-line …

Mar 8, 2023 · Other types of ALS Juvenile ALS. In most people, ALS develops in middle or late adulthood. Juvenile ALS, meanwhile, refers to disease that develops in patients younger than age 25.. This form of ALS is extremely rare, affecting fewer than 1,000 people in the U.S.. The age at onset and progression of juvenile ALS varies considerably — some cases are extremely …

Nov 22, 2024 · The upcoming trial intends to investigate the safety and effectiveness of two foralumab doses in 20 ALS patients. It builds on positive findings from multiple sclerosis (MS) patients, in whom the intranasal antibody therapy significantly decreased neuroinflammation and stabilized or reduced disability levels. Tiziana now wants to see if foralumab might also help in …

Oct 17, 2024 · The Scott-Morgan Foundation (SMF), a nonprofit that’s pioneering assistive technology innovation, will lead a new initiative using artificial intelligence (AI) technologies to help people with diseases like amyotrophic lateral sclerosis (ALS) to better communicate and maintain their sense of identity.

Oct 29, 2024 · Developed under a collaboration between the nonprofit Target ALS and Zephyrx, the database features respiratory function data collected remotely and over time using Zephyrx’s at-home spirometry technology.As of August, 68 patients were using the technology to collect measures of lung function as their disease evolves.

Dec 19, 2024 · In PARADIGM (NCT05357950), a completed Phase 2b study, PrimeC was tested against a placebo, both taken as two tablets by mouth twice daily for six months, in 68 adults diagnosed with ALS.Patients then had the option to enter an open-label extension where all received PrimeC for up to an additional 12 months. Consistent with earlier data, the 18-month …